iPSC-Derived Cardiomyocytes
Definition
Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) are heart muscle cells generated by reprogramming patient-derived somatic cells into pluripotent stem cells, then differentiating them into cardiomyocytes. They serve as patient-specific disease models that recapitulate the electrophysiological phenotype of the donor's genetic background.
Key Concepts
- iPSC-CMs are used as effective models for disease mechanisms and drug screening in channelopathies, including LQTS and BrS, because they carry the patient's exact genetic mutations. (sources/channelopathies-jaha-2025)
- High-throughput automated patch-clamp assays using iPSC-CMs allow evaluation of variants of uncertain significance (VUS) in cardiac ion channels, enabling variant-specific drug testing and genotype-guided therapy. (sources/channelopathies-jaha-2025)
- CRISPR/Cas9 editing in iPSC-CMs enables comparison of different variants, the same variant in different cell models, and homozygous vs. heterozygous mutations side by side. (sources/channelopathies-jaha-2025)
- Lumacaftor was shown to rescue the LQT2 phenotype in iPSC-CMs from LQT2 patients, leading to a phase II clinical trial (NCT04581408). (sources/channelopathies-jaha-2025)
- In silico models, genomics, transcriptomics, proteomics, and metabolomics complement iPSC-CM work to provide a systems biology understanding of disease severity and treatment response. (sources/channelopathies-jaha-2025)
- HCM disease modeling: hiPSC-CMs overcome limitations of human surgical specimens (late-stage only) and transgenic animals (species gap); allow complete patient gene map replication and enable longitudinal study of early-stage HCM mechanisms. (sources/HCM-VA-FCVMed-2022)
- CRISPR Ca²⁺ reporter lines: The Ca²⁺ indicator gene can be knocked into iPSC-CMs using CRISPR/Cas9 to generate Ca²⁺ reporter cell lines; confocal line-scan analysis directly visualizes arrhythmia-related Ca²⁺ signals; different sarcomere gene mutations show inconsistent contractility and molecular expression spectra → supports need for mutation-specific treatment. (sources/HCM-VA-FCVMed-2022)
- Machine learning of Ca²⁺ transients: Machine learning analysis of Ca²⁺ transient signal parameters from iPSC-CMs can differentiate HCM from LQT cardiac diseases, enabling scalable disease subtyping. (sources/HCM-VA-FCVMed-2022)
- Key limitation in HCM: Repolarization in hiPSC-CMs has little resemblance to mature adult ventricular myocytes; the intrinsic immaturity of intracellular Ca²⁺ handling mechanisms means iPSC-CMs may poorly recapitulate adult Ca²⁺ homeostasis; hiPSC-CMs do not necessarily replicate findings from transgenic animals with classical HCM mutations. (sources/HCM-VA-FCVMed-2022)
- EHT maturation strategies: Long-term culture on nanopatterned surfaces, 3D culture systems, and engineered heart tissue (EHT) methods improve maturity of hiPSC-CMs. (sources/HCM-VA-FCVMed-2022)
Contradictions / Open Questions
- iPSC-CM immaturity — limited Ca²⁺ handling fidelity: hiPSC-CM repolarization does not resemble mature adult ventricular myocytes; their intrinsic Ca²⁺ handling immaturity means they may not accurately recapitulate adult HCM or channelopathy phenotypes. Drug screening results in iPSC-CMs may not predict clinical response in adult patients. This is explicitly flagged as a key limitation of the HCM iPSC-CM literature. (sources/HCM-VA-FCVMed-2022)
- CRISPR Ca²⁺ reporter lines — heterogeneous mutation responses: Different sarcomere gene mutations show inconsistent contractility and molecular expression spectra in iPSC-CMs — supporting mutation-specific treatment, but also limiting the predictive value of any single iPSC-CM model for the broader disease category. (sources/HCM-VA-FCVMed-2022)
- Machine learning classification — channelopathy vs. HCM subtyping: ML analysis of Ca²⁺ transients in iPSC-CMs can distinguish HCM from LQTS. However, the clinical actionability of this subtyping is currently limited to research settings — no validated diagnostic pipeline using iPSC-CM + ML has entered clinical evaluation. (sources/HCM-VA-FCVMed-2022)
Connections
- Related to concepts/Ion-Channel-Mutations
- Related to concepts/CRISPR-Cas9-in-Channelopathies
- Related to entities/Long-QT-Syndrome
- Related to entities/Brugada-Syndrome
- Related to entities/CPVT
- Related to entities/HCM
- Related to concepts/Calcium-Homeostasis-in-HCM
- Related to concepts/Ion-Channel-Remodeling-in-HCM